US FDA approves AstraZeneca's drug for breast cancer
The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of breast cancer, the health regulator said on Friday. The treatment, jointly developed with the Japanese company,
AstraZeneca’s Datroway approved in U.S. for HER2-negative breast cancer patients
DXd, has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.
AstraZeneca Gets FDA Approval for Metastatic Breast Cancer Treatment Datroway
AstraZeneca said the U.S. Food and Drug Administration approved Datroway, a treatment for metastatic breast cancer developed in combination with Daiichi Sankyo. The Anglo-Swedish drugmaker on Friday said that the approval is for adult breast cancer patients who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.
FDA approves new MCL treatment by AstraZeneca
WILMINGTON, Del. - The U.S. Food and Drug Administration (FDA) has granted approval to AstraZeneca (NASDAQ:AZN)'s CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation.
Monthly Prescribing Reference12d
Novel Antibody-Drug Conjugate Gets Breakthrough Tx Designation for R/R Osteosarcoma
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to GSK5764227 (GSK’227) for the treatment of adult patients with relapsed or refractory (R/R) osteosarcoma who have ...
C&EN12d
Pfizer doubles down on AI partnership with antibody-drug conjugate deal
Pfizer is expanding its collaboration with the start-up PostEra, which applies artificial intelligence to medicinal chemistry ...
Yahoo Finance4d
Antibody Drug Conjugates Market Outlook 2025-2035, with Forecasts for Payload Type, Linker Type, Target Antigen and Applications
Dublin, Jan. 15, 2025 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates Market Report 2025-2035" has been added to ResearchAndMarkets.com's offering. World revenue for the Antibody Drug ...
조선일보5d
Celltrion targets innovative drug development with new ADC and antibody candidates
Celltrion targets innovative drug development with new ADC and antibody candidates Celltrion aims for growth by venturing ...
C&EN10d
Roche licenses Innovent antibody-drug conjugate
Roche has licensed an antibody-drug conjugate (ADC) designed to treat advanced small-cell lung cancer from China-based Innovent Biologics for $80 million up front and up to $1 billion in milestone ...
BioSpace9d
Boehringer Ingelheim Expands Cancer Pipeline With Back-to-Back Antibody Deals
Boehringer Ingelheim announced a partnership with Synaffix to advance antibody-drug conjugates and exercised its fourth ...
CSPC Pharma’s SYS6045 Antibody-Drug Gets China Clinical Trial Nod
Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...
Boehringer Ingelheim Acquires Fourth License for the Development of Novel Antibody Based Cancer Treatments from Oxford BioTherapeutics
Oxford, UK and San Jose, California, 9 January 2024 - Oxford BioTherapeutics (OBT), a clinical stage oncology company with a ...
Cancer Therapy Advisor12d
Novel Antibody-Drug Conjugate Gets Breakthrough Tx Designation for Rel/Ref Osteosarcoma
GSK5764227 (HS-20093) is a novel antibody-drug conjugate composed of a fully human anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor payload.
Biohaven And Merus Collaborate To Develop Novel Bispecific Antibody Drug Conjugates
Biohaven Ltd. (BHVN) and Merus N.V. (MRUS) announced a research collaboration and licensing agreement aimed at co-developing three ...